GAMMA Investing LLC Acquires Shares of 1,624 Sanofi (NASDAQ:SNY)

GAMMA Investing LLC bought a new position in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,624 shares of the company’s stock, valued at approximately $81,000.

A number of other large investors have also made changes to their positions in SNY. Rise Advisors LLC raised its position in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new position in shares of Sanofi during the 4th quarter worth $27,000. Venturi Wealth Management LLC increased its position in shares of Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in Sanofi by 115.6% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after buying an additional 400 shares during the period. Finally, CNB Bank acquired a new position in Sanofi in the third quarter valued at about $39,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research analyst reports. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Price Performance

Sanofi stock opened at $49.09 on Tuesday. The company’s 50 day moving average is $47.77 and its two-hundred day moving average is $48.28. The firm has a market cap of $124.18 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.48 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.93.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. On average, research analysts expect that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a $1.478 dividend. This represents a dividend yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.